PRCT - NASDAQ

PROCEPT BioRobotics Corporation

PRCT·NASDAQ

$26.84

+0.31%

HealthcareMedical - Devices

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.53B

EPS-1.7200

P/E Ratio-15.61

Earnings Date08/05/2026

-48.98M

Operating Cash Flow

-51%

3Y-39.0%

5Y+1.0%

10Y+12.0%

-9.36M

Investing Cash Flow

112%

3Y+253.0%

5Y+3915.0%

10Y-122.0%

11.19M

Financing Cash Flow

-94%

3Y+210.0%

5Y-90.0%

10Y-58.0%

PROCEPT BioRobotics Corporation Cash Conversion Engine

PRCT · NASDAQ

FCF Components

Net Income-95.57M

Depreciation & Amortization6.39M

Stock-Based Compensation47.60M

Change in Working Capital-7.84M

Others433.00K

Capital Expenditures-9.36M

Free Cash Flow-58.34M

Cash Flow Quality Analysis

FCF Conversion Rate

61.0%

Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.

CapEx Intensity

-19.1%

Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.

FCF Growth Trend

+43.7%

Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.

Working Capital Impact

-$7.84M

Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.

Cash Flow Quality Insight

Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.

PROCEPT BioRobotics Corporation Cash Flow Statement

PRCT • NASDAQ

PROCEPT BioRobotics Corporation Cash Flow Statement	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
OPERATING ACTIVITIES
Net Income	-95.6M	-91.4M	-105.9M	-87.2M	-59.9M	-53M	-42M
Depreciation & Amortization	6.4M	5.2M	3.8M	2.8M	3.3M	2.9M	1.5M
Change in Deferred Taxes	0.0	0.0	0.0	0.0	451K	0.0	0.0
Stock-Based Compensation	47.6M	31.8M	19.1M	10.3M	3.8M	2.2M	2M
Other Non-Cash Items	433K	2.5M	1.1M	5.1M	-345K	126K	-1.8M
Change in Working Capital	-7.8M	-47.3M	-26.2M	-11.5M	-4.7M	-483K	-3.5M
Cash from Operating Activities	-49M	-99.2M	-108M	-80.4M	-57.3M	-48.3M	-43.8M
INVESTING ACTIVITIES
Investments in Property, Plant, and Equipment	-9.4M	-4.4M	-25.2M	-2.7M	-592K	-233K	-7.6M
Sale/Maturity of Investments	0.0	0.0	0.0	0.0	0.0	0.0	50.8M
Cash from Investing Activities	-9.4M	-4.4M	-25.2M	-2.7M	-592K	-233K	(43.2M)
FINANCING ACTIVITIES
Net Issuance of Common Stock	11.2M	164.5M	161.7M	0.0	172.4M	0.0	0.0
Net Issuance of Debt	0.0	0.0	0.0	1.2M	0.0	24.7M	24.5M
Other Financing Items	0.0	15.6M	6.1M	2.4M	5M	5.6M	2M
Cash from Financing Activities	11.2M	180.1M	167.8M	3.6M	262.1M	106.8M	26.5M
CASH FLOW SUMMARY
Effect of Foreign Exchange Rates	-74K	0.0	0.0	0.0	0.0	0.0	0.0
Net Change in Cash	-47.2M	76.5M	34.6M	-79.4M	204.2M	58.2M	25.9M
Cash at Beginning of Period	336.8M	260.3M	225.7M	305.1M	100.9M	42.7M	16.9M
Cash at End of Period	289.5M	336.8M	260.3M	225.7M	305.1M	100.9M	42.7M
Free Cash Flow	-58.3M	-103.6M	-133.2M	-83M	-57.9M	-48.6M	-51.4M

SEC Filings

PRCT - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	April 30, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 29, 2026	April 29, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 22, 2026	June 09, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 06, 2026	March 05, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 25, 2026	February 25, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 05, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 04, 2025	November 04, 2025	2025	View Filing
8-K 8-K 2025 N/A	September 18, 2025	September 15, 2025	2025	View Filing

Showing 1 to 10 of 72 filings

Related Guides

Blog Categories

Continue your PRCT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.